PROTAGONIST THERAPEUTICS INC (PTGX) Stock Income Statement
NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 434.43M | 60.00M | 26.58M | 27.36M | 28.63M | |||
| Operating Expenses | 181.59M | 153.65M | 157.95M | 153.20M | 93.14M | |||
| Research and Development | 138.13M | 120.16M | 126.22M | 126.01M | 74.51M | |||
| Selling, General, and Administrative Expenses | 43.46M | 33.49M | 31.74M | 27.20M | 18.64M | |||
| Operating Income | 252.84M | -93.65M | -131.37M | -125.85M | -64.51M | |||
| Interest Income/Expense | 26.32M | 14.90M | 4.06M | 440.00K | 300.00K | |||
| Other Income/Expense | 250.00K | -201.00K | -80.00K | -150.00K | -50.00K | |||
| Non Recurring Items | N/A | N/A | 0.00 | 0.00 | -590.00K | |||
| Income Before Taxes | 279.41M | -78.95M | -127.39M | -125.55M | -64.85M | |||
| Income Tax | 4.22M | N/A | 0.00 | 0.00 | 1.31M | |||
| Net Income | 275.19M | -78.95M | -127.39M | -125.55M | -66.15M | |||
| EBITDA | 255.74M | -90.34M | -130.34M | -125.04M | -63.72M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 4.23 | -1.39 | -2.60 | -2.71 | -1.92 | |||
| Non GAAP EPS | 4.20 | -1.49 | -2.60 | -2.70 | -2.02 | |||
| Statistics | ||||||||
| Profit Margin | 63.34% | -131.59% | -479.27% | -458.88% | -231.05% | |||
| Operating Profit Margin | 58.20% | -156.09% | -494.24% | -459.98% | -225.32% | |||
All data in USD